By Eric Sagonowsky
Moderna and its partners in the federal government are just now gearing up for a late-stage COVID-19 vaccine trial set to launch later this month. But at the same time, the mRNA biotech is prepping a supply of doses for quick shipment if the shot gets an FDA go-ahead.
read more
By Paige Minemyer
A new study offers a look at the cost of COVID-19 hospitalizations and where patients are most likely to present with the virus.
read more
By Eric Sagonowsky
Gilead Science’s remdesivir is on the very short list of drugs that have posted positive data in COVID-19, but one U.S. lawmaker is joining a chorus arguing the company priced the medicine too high. Taxpayers spent nearly $100 million to save the drug from the "scrapheap," the lawmaker wrote, and are being repaid with "price gouging."
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
The FDA released a breakdown of its Coronavirus Treatment Accelerator Program, laying out its review process, regulatory milestones and more. A chance meeting led to a fat government contract for ApiJect and its as-yet-unapproved injector devices. And India-based generics maker Lupin was forced to idle a plant to quash an outbreak there.
read more
By Ben Adams
A new biotech has come out of stealth mode with a funding round that includes “celebrity investors in artificial intelligence” as it aims to tackle aging and perhaps even COVID-19.
read more
By Heather Landi
UNC officials are partnering with Google on an app to help healthcare workers find support amid the COVID-19 pandemic—and help health systems identify and proactively reach out to help units where more worker support is needed.
read more
By Angus Liu
No animal data, no word on the timeline for a clinical trial, yet one little-known Chinese company is already building a multimillion-dollar facility for a COVID-19 vaccine late-comer, even as several domestic programs are already in final stages of clinical testing.
read more
By Paige Minemyer
UnitedHealth Group reported $6.6 billion in profit for the second quarter, beating Wall Street projections.
read more
By Kyle Blankenship
As major drugmakers crusade for a COVID-19 vaccine, the problem of securing enough manufacturing capacity for global distribution has grown more acute. Seeing a future opportunity, one U.S. generics maker is making a big down payment to boost its own shot offerings.
read more
